(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 October 2008 (23.10.2008)

PCT

(10) International Publication Number
WO 2008/127199 A1

(51) International Patent Classification:
A61K 38/48 (2006.01) *G01N 33/53* (2006.01)
A61K 31/7088 (2006.01) *G01N 33/48* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/SG2008/000116

(22) International Filing Date: 11 April 2008 (11.04.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/911,573 13 April 2007 (13.04.2007) US

(71) Applicant *(for all designated States except US)*: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 20 Biopolis Way #07-01, Centros, Singapore 138668 (SG).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MILLER, Lance D** [US/SG]; Genome Institute of Singapore, 60 Biopolis Street #02-01, Genome, Singapore 138672 (SG). **LIM, Bing** [CA/SG]; Genome Institute of Singapore, 60 Biopolis Street #02-01, Genome, Singapore 138672 (SG). **ZHANG, Jinqiu** [CN/SG]; Genome Institute of Singapore, 60 Biopolis Street #02-01, Genome, Singapore 138672 (SG).

(74) Agent: **SCHIWECK, Wolfram**; Viering, Jentschura & Partner LLP, P.O. Box 1088, Rochor Post Office, Rochor Road, Singapore 911833 (SG).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(54) **Title:** METHODS OF CONTROLLING TUMORIGENESIS AND DIAGNOSING THE RISK THEREOF

Fig. 9A



(57) **Abstract:** The present invention relates to methods of controlling tumorigenesis, including preventing, inhibiting, arresting or reversing tumorigenesis. The present invention also provides methods of treatment, prevention and diagnosis of neoblastoma, including cancer, such as metastatic cancer. In one method one or more cells having a predisposition to turn tumorigenic are identifyied. In the one or more cells an altered amount, an altered subcellular localisation or an altered activity of a Rab binding protein is detected. In a method of diagnosing the risk of developing a neoplasmt at least one of the expression level, the activity level and the subcellular localisation of a Rab binding protein is determined. In an *in-vitro* method of identifying a compound capable of forming a complex with a Rab binding protein the components that form the respective complex are contacted with each other. In a method of determining whether a neoplasm is sensitive to an alteration of intracellular calcium levels, at least one of the expression and the activity of a Rab binding protein is determined. An altered expression or an altered activity of the Rab binding protein is an indication that the neoplasm is sensitive to an alteration of intracellular calcium levels.

WO 2008/127199 A1